Last reviewed · How we verify
NCT05130853: SoCIAL
Efficacy Study of a New Individualized Rehabilitation Programme for Social Cognition in Patients With Schizophrenia
NA trial testing Social Skills and Neurocognitive Individualized Training (SoCIAL) in Schizophrenia in 48 participants. Completed in 31 July 2022.
31 July 2022
Quick facts
| Lead sponsor | University of Campania Luigi Vanvitelli |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 10 January 2021 |
| Primary completion | 31 July 2022 |
| Estimated completion | 31 July 2022 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Social Skills and Neurocognitive Individualized Training (SoCIAL)
- Treatmment-as-usual
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
- Schizo Affective Disorder — all drugs for Schizo Affective Disorder →
Sponsor
University of Campania Luigi Vanvitelli
Who can join
Adults 18 to 50, any sex, with Schizophrenia or Schizo Affective Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients affected by schizophrenia often present significant deficits in various aspects of social cognition, such as social perception, recognition of one's own and other people's emotional state and the theory of mind. Recent studies investigated the correlation between social cognition and real-life functioning, reporting that greater social cognition deficits determine worse social and occupational functioning in real-life. Therefore, social cognition deficits represent an important target both in therapeutic and rehabilitative treatment in patients with psychotic conditions, especially in the early phases of the disease. Our research group has implemented a new individualized rehabilitation programme for social cognition: the Social Cognition Individualized Activities Lab, SoCIAL. The pivotal study showed that this programme improves specifically social cognition abilities, even when compared to a standardised and validated rehabilitation programme such as the Social Skills And Neurocognitive Individualized Training (SSANIT). However, the improvement in social cognition did not translate in improvement in real-life functioning. Recently, another key aspect that plays a role in quality of life and real life functioning in people with schizophrenia has emerged, the narrative abilities. Available data confirm that this variable has a strong impact on social functioning and quality of life in patients with schizophrenia. Taking into account the above evidence, our group decided to implement a new version of the social cognitive remediation programme in order to overcome the limitations found during its pivotal study. The new SoCIAL programme is characterized by specific modules for training of social cognition and narrative abilities in patients with schizophrenia. The efficacy of this programme, compared to treatment as usual, in individuals diagnosed with schizophrenia or schizoaffective disorder will be assessed. The generalization of improvement to real-life functioning domains will also be evaluated in completers and in the intent-to-treat sample.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Social Cognition Individualized Activities Lab for Social Cognition Training and Narrative Enhancement in Patients With Schizophrenia: A Randomized Controlled Study to Assess Efficacy and Generalization to Real-Life Functioning (Prot. n°: NCT05130853).
Palumbo D, Caporusso E, Piegari G, Mencacci C, et al · · 2022 · cited 6× · PMID 35444577 · DOI 10.3389/fpsyt.2022.833550 -
Effectiveness of a social cognition remediation intervention for patients with schizophrenia: a randomized-controlled study.
Giuliani L, Pezzella P, Mucci A, Palumbo D, et al · · 2024 · cited 2× · PMID 39732701 · DOI 10.1186/s12991-024-00535-9
Verify or expand the search:
- PubMed search for NCT05130853
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other University of Campania Luigi Vanvitelli trials
Trials by the same sponsor.
- NCT07590349 — Personalized Robotic Telerehabilitation for Upper Limb Functional Recovery After Stroke in a Home-Based Setting · NA · not yet recruiting
- NCT06718452 — Tinnitus and Treatment With umPEA-LUT · NA · not yet recruiting
- NCT07124676 — Prospective Study Comparing Two Classification Systems for Second-degree Vaginal Tears During Spontaneous Childbirth to · not yet recruiting
- NCT07425912 — Real-World Evaluation of TouchCare Nano in Pediatric Type 1 Diabetes · active not recruiting
- NCT06991816 — The Brain&Senses Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05130853 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Campania Luigi Vanvitelli
- Last refreshed: 31 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05130853.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing